pembrolizumab
merck
[]
asco gi. see our poster on sat 1/21, board c12, abstr 57. data on msi-h metastatic crc treated with 1st line pembro showing significantly poorer pfs with mets including liver vs non liver.
Professor Med Onc + GI, researcher @MayoClinic. Interests: #colorectalcancer, #GIcancer, therapeutics, #hereditarycancers. Views my own.@FASinicropeMD